Clinical trial
ACT34-CMI -- Adult Autologous CD34+ Cells
NCT00300053 · Lisata Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT00300053 |
|---|---|
| Title | ACT34-CMI -- Adult Autologous CD34+ Cells |
| Official title | A DB, Randomized, Placebo-controlled Study of the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial CLBS14 for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI) |
| Lead sponsor | Lisata Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myocardial Ischemia |
| Intervention type | Biological |
| Interventions | CLBS14 (low-dose), CLBS14 (high-dose), placebo injection |
| Enrollment | 321 |
| Start date | Apr 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Mar 8, 2006 |
| Last update posted | Jan 26, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: